Zum Hauptinhalt springen
xMedica

NCT07069673ClinicalTrials.gov

Abbott Cephea Mitral Valve Disease Registry

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding…

Beobachtend1.000 Teilnehmende gesucht24 Studienzentren1 Land

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-07-17; recorded start 2025-08-13
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 82 other studies in this databaseCounted from the lead sponsor named in the record (Abbott Medical Devices)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 7 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 23 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,000 participants (target), run at 24 sites.

How this score is built
  • Enrolment30/40

    1,000 participants (target)

  • Site count16/25

    23 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 40 months

  • Sponsor scale7/10

    Abbott Medical Devices has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of correcting symptomatic mitral valve disease on clinical outcomes in patients that could be candidates for Transcatheter Mitral Valve Replacement and may also inform future regulatory or reimbursement submission strategies for the Cephea Mitral Valve System.

Erkrankungen

  • Mitral Regurgitation
  • Mitral Stenosis
  • Mitral Valve Disease
  • Mitral Valve (MV) Regurgitation
  • Mitral Annulus Calcification
  • Mitral Valve Replacement
  • Transcatheter Valve Replacement

Eignung

Eignung
GeschlechtAlle
Alter18 YearsKein Höchstalter
Gesunde FreiwilligeNein
StichprobenverfahrenNON_PROBABILITY_SAMPLE

Studienpopulation

This registry will enroll subjects over 18 years of age of all genders with symptomatic mitral valve disease including those with mitral regurgitation, mitral stenosis, and mixed mitral valve disease, who are candidates for transcatheter mitral valve replacement.

Eignung im Wortlaut des Registers

Inclusion Criteria: 1. Symptomatic mitral valve disease resulting in mitral regurgitation and/or severe mitral valve stenosis. 2. New York Heart Association (NYHA) Functional Class II, III, or ambulatory IV. 3. In the judgement of the Site Heart Team, transcatheter therapy is deemed to be more appropriate than conventional mitral valve surgery, TMVR is more likely to provide an optimal result than TEER, and the subject has been adequately treated per applicable standards, including for coronary artery disease, left ventricular dysfunction, and heart failure. 4. Age 18 years or older at time of consent. 5. The subject agrees to the study requirements, permits all follow-up data entry, and has provided written informed consent. Exclusion Criteria: 1. Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function. 2. Subject is undergoing dialysis or experiencing chronic renal failure 3. Subject has chronic lung disease requiring continuous home oxygen therapy or chronic outpatient oral steroid use 4. Subjects with comorbidities that are likely to result in a life expectancy of less than 12 months. 5. Pregnant or nursing subjects and those who plan pregnancy during the follow-up period.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypBeobachtend
PhaseIm Registereintrag nicht angegeben
ZuteilungIm Registereintrag nicht angegeben
InterventionsmodellIm Registereintrag nicht angegeben
Primäres ZielIm Registereintrag nicht angegeben
VerblindungIm Registereintrag nicht angegeben
Teilnahme1.000 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Abbott Medical Devices Sponsor

Studienarme und Interventionen

  • Potential transcatheter mitral valve replacement (TMVR) candidates

    Patients with symptomatic mitral valve disease who may be candidates for transcatheter mitral valve replacement.

Endpunkte

  1. Primärer Endpunkt

    Primary Objective

    The objective of the MVD Registry is to collect data on the progression of MVD patients considered for TMVR therapy to guide product development, regulatory submissions, and reimbursement planning

    Zeitrahmen From enrollment to 2 years of follow-up

Daten

Daten
Startdatum13. August 2025 (tatsächlich)
Primärer Abschluss1. Dezember 2028 (geschätzt)
Abschluss1. Dezember 2028 (geschätzt)
Erstveröffentlichung17. Juli 2025 (tatsächlich)
Zuletzt aktualisiert10. September 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtJuni 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

24 Studienzentren rekrutieren

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Piedmont Heart InstituteAtlantaGeorgiaRekrutiert
Emory University HospitalAtlantaGeorgiaRekrutiert
University Hospital - Univ. of Alabama at Birmingham (UAB)BirminghamAlabamaRekrutiert
Medical University of South CarolinaCharlestonSouth CarolinaRekrutiert
Atrium Health - Carolinas Medical CenterCharlotteNorth CarolinaRekrutiert
Northwestern Memorial HospitalChicagoIllinoisRekrutiert
The Cleveland Clinic FoundationClevelandOhioRekrutiert
Houston MethodistHoustonTexasRekrutiert
UTHealth Memorial HermannHoustonTexasRekrutiert
Ascension St. VincentIndianapolisIndianaRekrutiert
Minneapolis Heart InstituteMinneapolisMinnesotaRekrutiert
Providence St. Patrick HospitalMissoulaMontanaRekrutiert
Intermountain Medical CenterMurrayUtahRekrutiert
Ascension Saint ThomasNashvilleTennesseeRekrutiert
Vanderbilt Heart & Vascular InstituteNashvilleTennesseeRekrutiert
TriStar Centennial Medical CenterNashvilleTennesseeRekrutiert
Sentara Norfolk General HospitalNorfolkVirginiaRekrutiert
Banner-University Medical Center PhoenixPhoenixArizonaRekrutiert
Phoenix Cardiovascular Research GroupPhoenixArizonaRekrutiert
Allegheny General Hospital - ASRIPittsburghPennsylvaniaRekrutiert
St. Francis HospitalRoslynNew YorkRekrutiert
Montefiore Medical Center - Moses CampusThe BronxNew YorkRekrutiert
Los Robles Regional Medical CenterThousand OaksCaliforniaRekrutiert
Ascension Via Christi Hospitals WichitaWichitaKansasRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 10. September 2026

    Studienzentrum hinzugefügt

    1 site added (24 total)

    2324